NCT03066947 2021-01-29SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerBriaCell Therapeutics CorporationPhase 1/2 Completed24 enrolled 12 charts
NCT03552549 2019-07-24SCH 54031 PEG12000 Interferon Alfa-2b (PEG Intron, MK-4031) vs. INTRON®A (SCH 30500, MK-2958) as Adjuvant Therapy for Melanoma (C98-135, MK-4031-002)Merck Sharp & Dohme LLCPhase 2/3 Terminated126 enrolled 9 charts
NCT00613509 2016-04-14Study of a Multi-Antigen Therapeutic Vaccine in Patients With Metastatic MelanomaSanofiPhase 2 Terminated23 enrolled 14 charts
NCT00749684 2015-10-19Efficacy and Safety of High-dose Interferon Alfa-2b (Intron A®) for the Adjuvant Treatment of Malignant Melanoma (Study P04083)Merck Sharp & Dohme LLCCompleted138 enrolled 6 charts
NCT00723710 2015-08-26Effect of Proactive Management of Side Effects on Treatment Compliance in Malignant Melanoma Patients on High-dose Intron A Therapy (Study P04600)Merck Sharp & Dohme LLCCompleted299 enrolled 5 charts